Table 3 Medication and association with HbA1c
From: Characteristics of poorly controlled Type 2 diabetes patients in Swiss primary care
Mean ± SD or n (%) | Association with HbA1c1) | ||
|---|---|---|---|
Coefficient | P-value | ||
Anitdiabetic therapy | 312 (96.6) | 0.022 c), 3d) | |
None (n, %) | 12 (3.7) | ||
Only oral (n, %) 2) | 208 (64.4) | ||
Only insulin (n, %) 2) | 26 (8.0) | ||
Combined (insulin and oral) (n, %) 2) | 77 (23.8) | ||
Specific antidiabetic therapies | |||
Insulin (n, %) | 103 (31.9) | 0.005 b), 3e) | |
Metformin/Biguanid (%) | 254 (78.6) | 0.384 b) | |
Sulfonylurea (n, %) | 136 (42.1) | 0.764 b) | |
Gliptine (DPP-III) (n, %) | 44 (13.6) | 0.425 b) | |
Glitazone (n, %) | 19 (5.9) | 0.553 b) | |
Glinide (n, %) | 10 (3.1) | 0.160 b) | |
Incretin mimetic (n, %) | 6 (1.9) | 0.090 b) 3f) | |
α-Glucosidase inhibitor (n, %) | 4 (1.2) | 0.837 b) | |
Any antihypertensive agent (n, %) 2) | 246 (76.2) | 0.098 b), 3g) | |
Diuretics (n, %) | 160 (49.5) | 0.317 b) | |
Inhibitor of the angiotensin converting enzyme (ACE-I) (n, %) | 156 (48.3) | 0.213 b) | |
Beta-blocker (n, %) | 101 (31.3) | 0.321 b) | |
Angiotensin II inhibitor (ARB) (n, %) | 70 (21.7) | 0.787 b) | |
Calcium antagonists (n, %) | 64 (19.8) | 0.135 b) | |
others (n, %) | 4 (1.2) | 0.838 b) | |
Any antiplatelet therapy (n, %) 2) | 179 (55.4) | 0.700 b) | |
Aspirin (n, %) | 158 (48.9) | 0.869 b) | |
Phenprocoumon (n, %) | 21 (6.5) | 0.017 b), 3h) | |
Clopidogrel (n, %) | 17 (5.3) | 0.505 b) | |
Any lipid-lowering therapy (n, %) 2) | 182 (56.3) | 0.005 b), 3i) | |
Any antidepressants (n, %) | 37 (11.5) | 0.751 b) | |
Number of drugs total | 4.8 (2.1) | -0.052 | 0.349 a) |